Key result
Gemcitabine linked to ~5% incidence of new-onset CHF, driven by high cumulative doses.
Why the study?
The incidence and clinical features predisposing to new-onset congestive heart failure in patients receiving gemcitabine were not well characterized.
Does gemcitabine dose or other clinical features predispose female patients with solid cancers to new-onset congestive heart failure?
Population
156 female patients with ovarian and other solid cancers receiving gemcitabine
Comparison
Patients with new-onset congestive heart failure vs patients without new-onset congestive heart failure
Design
Retrospective chart review cohort study
Authors
Loading...
May warrant closer cardiac monitoring in gemcitabine recipients with diabetes, CAD, or cumulative dose >17 000 mg/m²; leaves open prospective validation of risk thresholds.
Cohort (n=156)
Does gemcitabine dose or other clinical features predispose female patients with solid cancers to new-onset congestive heart failure?
Absolute Event Rate: 4.5% vs 0.76%
Gemcitabine therapy is associated with a 4.5% incidence of new-onset congestive heart failure, with cumulative doses >17,000 mg/m2 identified as the single-most predictive risk factor.
Shrum et al. (2013) conducted a cohort in Ovarian and other solid cancers (n=156). Gemcitabine vs. Previously reported incidence was evaluated on New-onset congestive heart failure. Gemcitabine exposure in female patients with solid tumors was associated with a 4.5% incidence of new-onset congestive heart failure, with cumulative doses >17,000 mg/m2 being the strongest predictor.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: